HeartBeam and Mount Sinai Announce Strategic AI Collaboration

HeartBeam Inc. has forged a strategic collaboration with the Icahn School of Medicine at Mount Sinai (New York) to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership is part of HeartBeam’s long-term strategy to build an ecosystem around its platform and strengthen its market position in artificial intelligence (AI)-enabled cardiac monitoring. 

The collaboration aims to leverage HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from three non-coplanar dimensions. A core value driver of the collaboration is HeartBeam’s ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—information that has historically been inaccessible to AI development. This creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings, supporting both wellness use cases and clinically relevant assessments, such as heart attack risk. 

The combination of HeartBeam’s continuously expanding dataset and Mount Sinai’s clinically annotated 12-lead ECG data can accelerate the training and validation of various AI models. Over time, this collaboration will result in a data engine that is expected to support the development of increasingly personalized algorithms—positioning HeartBeam to expand into new clinical indications and reimbursement pathways.

“We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities,” HeartBeam CEO Robert Eno said. “By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai’s extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity.”

Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, Ph.D., a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train, and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Helping to guide the partnership’s scientific and clinical development are Joshua Lampert, M.D., a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care; Vivek Reddy, M.D., an internationally renowned electrophysiologist and innovator; and Girish N. Nadkarni, M.D., chief AI officer of the Mount Sinai Health System and chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai.

“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems,” said Dr. Lampert, a cardiac electrophysiologist, medical director of Machine Learning for Mount Sinai Fuster Heart Hospital, and director of Cardiovascular Artificial Intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai. “Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional healthcare settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs. By combining deep learning tools with the ability to record full three-dimensional cardiac electrical activity without cables, we can provide clinically meaningful and operationally pragmatic models at scale regardless of environment.”

Pairing HeartBeam’s hardware and approach to cardiac waveform engineering with Mount Sinai’s advanced AI and clinical expertise creates a powerful foundation for developing tools that dynamically meet modern patient and clinician needs, experts claim.

“Heart disease doesn’t only show up during a brief visit to the clinic. This collaboration gives us an opportunity to bring powerful clinical-grade heart monitoring into patients’ daily lives,” Dr. Nadkarni stated. “By combining advanced AI with HeartBeam’s ability to capture full 12-lead ECG signals from home over time, we can study the heart in ways that simply haven’t been possible before—helping clinicians detect risk earlier and guide care more precisely.”

Together, the two organizations aim to accelerate the development of high-value algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. By enabling AI models to operate on longitudinal, real-world, synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms. 

“This collaboration addresses an important need by leveraging deep learning and three-dimensional waveform data for scalable diagnostic and predictive purposes, allowing insights beyond even expert human ability,” added Dr. Reddy, who directs cardiac arrhythmia services for Mount Sinai Health System.

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, over 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai discovers and applies new scientific learning and knowledge; develops safer, more effective treatments; educates the next generation of medical leaders and innovators; and supports local communities by delivering high-quality care. 

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive healthcare solutions from birth through geriatrics, leveraging innovative approaches such as AI and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report’s “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report “Best Hospitals” Honor Roll for 2025-2026. 

HeartBeam Inc. is a medical technology company transforming the detection and monitoring of critical cardiac conditions. The company is creating the first cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. HeartBeam’s 3D ECG technology received U.S. Food and Drug Administration clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025. The company holds more than 20 issued patents related to technology enablement.